# Real-world First-line Serplulimab-based Immunochemotherapy for Extensive-stage Small Cell Lung Cancer

> **NCT06748495** · — · ACTIVE_NOT_RECRUITING · sponsor: **Hunan Cancer Hospital** · enrollment: 600 (estimated)

## Conditions studied

- Extensive-stage Small Cell Lung Cancer (ES-SCLC)

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06748495
- **Lead sponsor:** Hunan Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-02-05
- **Primary completion:** 2024-12-30
- **Final completion:** 2025-06-06
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2025-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06748495

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06748495, "Real-world First-line Serplulimab-based Immunochemotherapy for Extensive-stage Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06748495. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*